PT  - JOURNAL ARTICLE
AU  - Badawi, Rehab
AU  - Fahmy Abou Taira, Naglaa Samy
AU  - Hasby, Sara Essam
AU  - Elkhalawany, Walaa
AU  - Elrefaey, Waleed
AU  - Ahmed Khalf, Nahla
AU  - Ibrahim Okda, Hanaa
TI  - The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease
AID  - 10.15537/smj.2024.45.10.20240393
DP  - 2024 Oct 01
TA  - Saudi Medical Journal
PG  - 1034--1040
VI  - 45
IP  - 10
4099  - http://smj.org.sa/content/45/10/1034.short
4100  - http://smj.org.sa/content/45/10/1034.full
SO  - Saudi Med J2024 Oct 01; 45
AB  - Objectives: To examine the relation between liver fibrosis and chronic kidney disease (CKD) in metabolic-associated fatty liver disease (MAFLD) patients and its risk factors.Methods: The current study was carried out at Tanta University Hospital, Tanta, Egypt, from May 2021 to January 2023 and included 84 MAFLD patients with CKD and 80 MAFLD patients without CKD. All participants had been examined by abdominal ultrasonography and transient elastography with controlled attenuation parameter.Results: Chronic kidney disease patients exhibited a greater incidence of fibrosis compared to patients without CKD (75.6% vs. 24.4%). Logistic analysis demonstrated that the presence of multiple health conditions, such as MAFLD, diabetes mellitus, hypertension, and cardiovascular disease, were individually linked to CKD. Gender and body mass index were not independent factors related to CKD. Additionally, factors such as age, hyperuricemia, hypertriglyceridemia, hypercholesterolemia, hypoalbuminemia, hyperbilirubinemia, and viral hepatitis, apart from MAFLD comorbidities, were independently linked to CKD.Conclusion: Chronic kidney disease may represent a potential risk influence for liver fibrosis development in MAFLD patients.